Ausgabe 3/2016
Inhalt (15 Artikel)
Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors
Jan-Paul Bohn, Georg Pall, Guenther Stockhammer, Michael Steurer
Systematic Review of the Side Effects Associated With Anti-HER2-Targeted Therapies Used in the Treatment of Breast Cancer, on Behalf of the EORTC Quality of Life Group
Samantha C. Sodergren, Ellen Copson, Alice White, Fabio Efficace, Mirjam Sprangers, Deborah Fitzsimmons, Andrew Bottomley, Colin D. Johnson
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
Fotios Loupakis, Alexander Stein, Marc Ychou, Frank Hermann, Antonieta Salud, Pia Österlund
Acceleration of Proteinuria without Significant Impact on Renal Function and Its Protection by Angiotensin II Receptor Blocker in Rats Treated with Axitinib
Satoshi Imai, Hideaki Miyake, Masato Fujisawa
Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer
John Sarantopoulos, Monica M. Mita, Michael J. Birrer, Lee D. Cranmer, Luis T. Campos, Xiaoping Zhang, Penelope Bristow, Hidekuni Kaito, Vincent Strout, Luis H. Camacho
Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents
Hideaki Miyake, Mototsugu Muramaki, Satoshi Imai, Ken-ichi Harada, Masato Fujisawa
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer
Filippo Pietrantonio, Filippo de Braud, Massimo Milione, Claudia Maggi, Roberto Iacovelli, Katia Fiorella Dotti, Federica Perrone, Elena Tamborini, Marta Caporale, Rosa Berenato, Giorgia Leone, Alessio Pellegrinelli, Ilaria Bossi, Fabrizio Festinese, Stefano Federici, Maria Di Bartolomeo
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis
Francesco Massari, Chiara Ciccarese, Anna Caliò, Enrico Munari, Luca Cima, Antonio Benito Porcaro, Giovanni Novella, Walter Artibani, Teodoro Sava, Albino Eccher, Claudio Ghimenton, Francesco Bertoldo, Aldo Scarpa, Nicola Sperandio, Camillo Porta, Vincenzo Bronte, Marco Chilosi, Giuseppe Bogina, Giuseppe Zamboni, Giampaolo Tortora, Hemamali Samaratunga, Guido Martignoni, Matteo Brunelli
Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells
J. U. Schmohl, M. K. Gleason, P. R. Dougherty, J. S. Miller, D. A. Vallera
Rare RAS Mutations in Metastatic Colorectal Cancer Detected During Routine RAS Genotyping Using Next Generation Sequencing
Alexandre Harlé, Pierre Filhine-Tresarrieu, Marie Husson, Romain Boidot, Marie Rouyer, Cindy Dubois, Agnès Leroux, Jean-Louis Merlin
Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status
Florence Huguet, Marie Fernet, Nicole Giocanti, Vincent Favaudon, Annette K. Larsen
Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy
Eric Van Cutsem, Florence Joulain, Paulo M. Hoff, Edith Mitchell, Paul Ruff, Radek Lakomý, Jana Prausová, Vladimir M. Moiseyenko, Guy van Hazel, David Cunningham, Dirk Arnold, Hans-Joachim Schmoll, Albert J. ten Tije, Joseph McKendrick, Hendrik Kröning, Yves Humblet, Cristina Grávalos, Solenn Le-Guennec, Michael Andria, Emmanuelle Dochy, Raghu L. Vishwanath, Teresa Macarulla, Josep Tabernero
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
J. Mateo, V. Moreno, A. Gupta, S. B. Kaye, E. Dean, M. R. Middleton, M. Friedlander, C. Gourley, R. Plummer, G. Rustin, C. Sessa, K. Leunen, J. Ledermann, H. Swaisland, A. Fielding, W. Bannister, S. Nicum, L. R. Molife
Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
Sohita Dhillon
Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
Evelyn Despierre, Ignace Vergote, Ryan Anderson, Corneel Coens, Dionyssios Katsaros, Fred R. Hirsch, Bram Boeckx, Marileila Varella-Garcia, Annamaria Ferrero, Isabelle Ray-Coquard, John A. Green, Christopher Steer, Els M. J. J. Berns, Antonio Casado, Diether Lambrechts, Antonio Jimeno